BioWorld

March 5, 2003

View Archived Issues

ILEX Gets Non-Oncology Rights To Campath Leukemia Treatment

In Vivo Adenoviral Gene Transfer Inefficient In Aged Cardiac Muscle In Comparison With Adult Hearts

YM BioSciences Receives FDA Nod For Phase III Cancer Trial

Viragen Continues Restructuring To Sustain Remaining Resources

Aphton Releases Phase III Data, Prepares For Regulatory Filings

Other News To Note

TNF Drugs Not Implicated In Lymphoma Risk, Panel Says

The risk of lymphoma in the rheumatoid arthritis population doesn't appear to increase among patients taking a TNF blocker, members of an FDA advisory panel said on Tuesday. (BioWorld Today) Read More

Today's news in brief

BioWorld

BioWorld briefs for Aug. 22, 2025.

Today's news in brief

BioWorld MedTech

BioWorld MedTech briefs for Aug. 21, 2025.

FDA approved icons and medical professional

Ionis gets approval for preventing attacks in rare and genetic HAE

BioWorld

In Ionis Pharmaceuticals Inc.’s second U.S. FDA approval in under a year, the agency approved Dawnzera (donidalorsen) as a prophylactic therapy in the rare and...

Elderly woman holding illustration of brain with missing puzzle piece

Marvel Biotechnology’s MB-204 as therapeutic agent for Alzheimer’s disease

BioWorld Science

Phosphorylation of the protein Tau is a key post-translational feature in tauopathies like Alzheimer’s disease (AD), which leads to microtubule dysfunction and...

Wooden blocks spelling TARIFFS with a U.S. flag on top, placed on a map of Europe

EU, US lock in 15% max Rx tariff, no relief for medtech

BioWorld

No matter what level of tariff the Trump administration ends up imposing on biopharmaceuticals across the world, drugs and their precursors originating in the EU...